Unlock instant, AI-driven research and patent intelligence for your innovation.

Omega-3 fatty acid composition for preventing and/or treating cachexia

A technology of fatty acid and composition, applied in the field of composition of polyunsaturated omega-3 fatty acids such as EPA and DHA acid, which can solve the problems of reduced absorption of nutrients such as omega-3 fatty acids, decreased cell function, etc.

Inactive Publication Date: 2019-08-16
BASF CORP
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This can lead to decreased absorption of nutrients such as omega-3 fatty acids due to decreased cellular function
Additionally, these patients often suffer from diarrhea, another side effect of current cancer treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Omega-3 fatty acid composition for preventing and/or treating cachexia
  • Omega-3 fatty acid composition for preventing and/or treating cachexia
  • Omega-3 fatty acid composition for preventing and/or treating cachexia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0130] 1. A composition comprising a fatty acid oil mixture comprising at least 50% by weight of at least one fatty acid selected from EPA and DHA based on the weight of the fatty acid oil mixture, and wherein at least 15% by weight of the fatty acid oil mixture % Of fatty acids are in the form of monoacylglycerides.

[0131] 2. The composition according to embodiment 1, wherein at least 20% by weight, preferably 40-60% by weight of fatty acids of the fatty acid oil mixture are in the form of monoacylglycerides.

[0132] 3. The composition according to embodiment 1, wherein 15-95% by weight of the fatty acid oil mixture, preferably 20-70% by weight, especially 20-60% by weight, especially 20-30% by weight, particularly preferably 20- 25% by weight of fatty acids are in the form of monoacylglycerides.

[0133] 4. The composition according to any one of embodiments 1 to 3, wherein the amount of fatty acid alkyl ester is up to 10% by weight, preferably 0 to 5% by weight, based on the w...

Embodiment approach 1 to 40

[0185] -The composition of any one of embodiments 1 to 40, and

[0186] -Intestinal device,

[0187] Wherein the composition is filled into the intestinal device.

[0188] 50. The tube feeding formulation according to embodiment 49, wherein the intestinal device is a hand-held dispenser, preferably, wherein the hand-held dispenser comprises: i) a flexible body part that provides a reservoir for the composition of the present invention, said The flexible body part includes a wall material compatible with the composition, wherein the flexible body part is arranged thereon; ii) an outlet that can be connected to the feed pipe.

[0189] 51. The composition according to any one of embodiments 1 to 40 for use in the therapeutic and / or prophylactic treatment of cachexia.

[0190] 52. The composition according to any one of embodiments 1 to 40, which is used for the therapeutic and / or prophylactic treatment of cachexia in patients, wherein the underlying disease of cachexia is cancer, chronic ...

Embodiment 1

[0230] Example 1: Improved absorption of EPA / DHA in the form of a mixture of glycerides; miniature pig study

[0231] At 8 heads A pharmacokinetic study was run in minipigs to compare the bioavailability of monoacylglyceride formulations with the equivalent ethyl ester form of omega-3 fatty acid oil. Minipigs were dosed in a crossover design to obtain data on two oils from all eight animals. No. 1 oil contains 46w / w% EPA and 38w / w% DHA, which are formulated as a mixture of 20w / w% monoacylglycerides, 53w / w% diacylglycerides and 26w / w% triacylglycerides (glycerides mixture). Oil No. 2 contains 46w / w% EPA and 38w / w% DHA in ethyl ester form. Each animal was given 2 grams of oil. A total of 9 blood samples were taken from the animals after administration at the following time points: before treatment and 1, 2, 4, 6, 8, 12, 24 and 36 hours after treatment. Analyze the plasma concentration of EPA and DHA, and the results are related to the dose.

[0232] figure 1 Provides baseline ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions of polyunsaturated omega-3 fatty such as of (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoicacid (EPA) and (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoicacid (DHA) for preventing and / or treating cachexia in a subject. Particularly, the compositions comprise a certain amount of the fatty acids as monoacylglycerides. Further, the compositionsof omega-3 fatty acids preferably comprise a certain ratio of the fatty acids as mono-, di- and triacylglycerides as this enhances the digestion and uptake of the EPA and DHA fatty acids. Further, the invention relates to a method of preventing and / or treating cachexia in a subject, including administering a composition of EPA and DHA to the subject, wherein at least a part of the fatty acids areprovided in monoacylglyceride form.

Description

[0001] Invention field [0002] The present invention relates to a method of preventing and / or treating cachexia in an individual, the method comprising administering to the individual a polyunsaturated omega-3 fatty acid such as (5Z, 8Z, 11Z, 14Z, 17Z)-eicosan-5, 8, 11, Combination of 14,17-pentaenoic acid (EPA) and (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid (DHA) Things. [0003] Furthermore, the present invention discloses a composition of polyunsaturated omega-3 fatty acids such as EPA and DHA acids for use in the therapeutic and / or prophylactic treatment of cachexia by administering the composition to an individual. [0004] Background of the invention [0005] Dietary polyunsaturated fatty acids (PUFAs), including omega-3 PUFAs, have effects on various physiological processes affecting normal health and chronic diseases, such as regulating plasma lipid levels, cardiovascular and immune functions, insulin action, neuronal development and vision Features. [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/232A23L33/12A61K9/00A61K9/48A61P3/00A61P3/02
CPCA61K9/0029A61K9/4825A61K9/4858A61K31/232A23L33/12A23V2002/00A61K31/202A61P1/14A61P11/00A61P19/02A61P21/00A61P29/00A61P3/00A61P3/02A61P35/00A61P39/06A61P43/00A61P9/04A61K2300/00A23V2200/306A23V2200/308A23V2250/1868A23V2250/187A61K31/201A61K31/355A61K9/0053
Inventor H·尼汉姆I·M·沃尔德L·N·拉森S·O·哈斯特维特
Owner BASF CORP